Shanghai Henlius Biotech, Inc.
2696
Rang in aandelen
#4287
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise,... Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Aandeelprijs
$6.75
Marktkapitalisatie
$3.68B
Verandering (1 dag)
2.73%
Verandering (1 jaar)
-28.19%
Land
CN
Handel Shanghai Henlius Biotech, Inc. (2696)
Categorie
Healthcare
Operationele marge voor Shanghai Henlius Biotech, Inc. (2696)
Operationele marge op October 2026 TTM: 12.06%
Volgens de meest recente financiële rapporten en aandelenkoers van Shanghai Henlius Biotech, Inc. is de huidige operationele marge (TTM) 12.06%. Eind 2023 had het bedrijf een operationele marge van 11.71%.
Geschiedenis van de operationele marge van Shanghai Henlius Biotech, Inc. van 2017 tot 2026
Operationele marge aan het einde van elk jaar
| Jaar | Operationele Marge | Wijzigen |
|---|---|---|
| 2026 (TTM) | 12.06% | -26.51% |
| 2024 | 16.41% | 40.14% |
| 2023 | 11.71% | -159.90% |
| 2022 | -19.55% | -50.56% |
| 2021 | -39.54% | -74.88% |
| 2020 | -157.42% | -82.57% |
| 2019 | -903.13% | -85.32% |
| 2018 | -6,151.77% | 541.95% |
| 2017 | -958.30% | 0.00% |
Operationele marge van vergelijkbare bedrijven of concurrenten
| Bedrijf | Operationele Marge | Verschil in operationele marge | Land |
|---|---|---|---|
| 38.59% | -96.80% |
US
|
|
| -149.01% | -112.36% |
US
|
|
| 25.57% | -97.88% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -97.61% |
NL
|
Wat is de Operationele marge van een bedrijf?
De Operationele marge is een belangrijke indicator om de winstgevendheid van een bedrijf te beoordelen. Hogere operationele marges zijn over het algemeen beter omdat ze aangeven dat een bedrijf zijn producten of diensten veel duurder kan verkopen dan de productiekosten. De Operationele marge wordt berekend door de winst van een bedrijf te delen door de omzet.